The theme for Bactiguard in 2022 were its investments in product development, regulatory issues, production capacity and commercial ability relating both to BIP sales and to licensing. This platform for future growth will, we believe, again be emphasised in the Q4/22 results and, with investment being sustained in 2023, it should materialise into stronger operating leverage in the medium to long term.

https://research.sebgroup.com/corporate/reports/118544

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.